API

Mechanism of Action

The mechanism of action of ziprasidone, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug’s efficacy in schizophrenia is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism. As with other drugs having efficacy in bipolar disorder, the mechanism of action of ziprasidone in bipolar disorder is unknown.

Indication

GEODON is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of GEODON to prolong the QT interval and may consider the use of other drugs first GEODON is indicated as an oral formulation for the:

Treatment of schizophrenia.

• Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in adult patients with schizophrenia. (14.1) Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder.
• Adults: Efficacy was established in two 3-week trials in adult patients with manic or mixed episodes. Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate.
• Adults: Efficacy was established in one maintenance trial in adult patients. GEODON as an intramuscular injection is indicated for the: Acute treatment of agitation in schizophrenic patients.
• Adults: Efficacy was established in two short-term trials in agitated patients with schizophrenia.